Jentadueto

Jentadueto is a fixed-dose combination tablet containing linagliptin (a DPP-4 inhibitor) and metformin hydrochloride, used for the treatment of type 2 diabetes in adults when both components are appropriate and the patient's current regimen requires them. It offers the complementary blood glucose-lowering effects of both medicines in a single tablet.

Linagliptin: A Unique DPP-4 Inhibitor

Linagliptin stands out among DPP-4 inhibitors because it is predominantly excreted via the bile and gut (enterohepatic recirculation) rather than renally. This means that, unlike sitagliptin or saxagliptin, linagliptin does not require dose adjustment in patients with renal impairment, making it a particularly suitable option for patients with type 2 diabetes and chronic kidney disease (CKD).

Clinical Benefits

Jentadueto improves glycaemic control (HbA1c reduction) through the combined glucose-lowering effects of linagliptin and metformin, with a low risk of hypoglycaemia and no weight gain when used without insulin or sulfonylureas.

How to Take Jentadueto

Take Jentadueto twice daily with meals to reduce gastrointestinal side effects from the metformin component. Swallow tablets whole with water, do not crush or chew. Take at the same times each day for stable blood glucose control.

Dose

Common doses are Jentadueto 2.5 mg/850 mg or 2.5 mg/1000 mg twice daily. The total daily linagliptin dose is 5 mg (2.5 mg twice daily). The metformin dose is determined by individual need and kidney function, up to a maximum of 2000 mg daily. Jentadueto XR (extended-release) is also available for once-daily dosing.

Jentadueto is available in linagliptin 2.5 mg/metformin 850 mg and 2.5 mg/1,000 mg tablets. Take twice daily with meals. Jentadueto XR is available for once-daily dosing. Unlike other DPP-4/metformin combinations, Jentadueto does not require dose adjustment solely for renal impairment (as linagliptin is renally excreted in minimal amounts), though standard metformin renal restrictions apply.

Common Side Effects

Gastrointestinal symptoms from the metformin component (nausea, diarrhoea, abdominal pain) are the most common side effects and are best managed by taking the tablet with food and by gradual dose initiation. Nasopharyngitis and upper respiratory tract infection are associated with the linagliptin component.

Serious Rare Effects

Pancreatitis has been reported with DPP-4 inhibitors including linagliptin; stop Jentadueto and seek urgent medical assessment if you develop persistent severe abdominal pain. Joint pain (arthralgia) can be severe and disabling in some patients; contact your prescriber if you experience significant joint pain during treatment. Bullous pemphigoid has been reported rarely with DPP-4 inhibitors.

Follow the same precautions as for metformin regarding iodinated contrast media and acute illness. Although linagliptin does not require dose adjustment for renal impairment, the metformin component does. Stop Jentadueto if eGFR falls below 30 mL/min. Pancreatitis risk: do not restart after a confirmed episode. Monitor for hypoglycaemia if used with insulin or sulfonylureas. Hepatic impairment: linagliptin has no significant hepatic accumulation, but caution is advised and metformin is generally avoided in severe hepatic impairment.

Contraindicated in patients with eGFR below 30 mL/min/1.73m², diabetic ketoacidosis, metabolic acidosis, severe hepatic impairment, and known hypersensitivity to linagliptin, metformin, or any excipient. Not for use in type 1 diabetes.